MedTrace Logo

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

NCT06716151 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-01-20

No results posted yet for this study

Summary

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.

Conditions

  • Healthy

Interventions

DRUG

HB0034

Recombinant Humanized Anti-IL-36R Monoclonal antibody

DRUG

HB0034 matching placebo

HB0034 matching Palcebo

Sponsors & Collaborators

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-06
Primary Completion
2025-11-20
Completion
2025-11-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716151 on ClinicalTrials.gov